MX2020005555A - Construcciones inmunogenicas de peptidos de tau. - Google Patents
Construcciones inmunogenicas de peptidos de tau.Info
- Publication number
- MX2020005555A MX2020005555A MX2020005555A MX2020005555A MX2020005555A MX 2020005555 A MX2020005555 A MX 2020005555A MX 2020005555 A MX2020005555 A MX 2020005555A MX 2020005555 A MX2020005555 A MX 2020005555A MX 2020005555 A MX2020005555 A MX 2020005555A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide immunogen
- immunogen constructs
- tau peptide
- directed
- present disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
La presente descripción se dirige a construcciones inmunogénicas de péptidos individuales que se dirigen a partes de la proteína Tau para el tratamiento y/o prevención de tauopatías. La presente descripción también se dirige a composiciones que contienen las construcciones de inmunógenos peptídicos, métodos para producir y utilizar las construcciones de inmunógenos peptídicos y anticuerpos producidos por las construcciones de inmunógenos peptídicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762578124P | 2017-10-27 | 2017-10-27 | |
PCT/US2018/057840 WO2019084488A1 (en) | 2017-10-27 | 2018-10-26 | IMMUNOGENIC CONSTRUCTS OF PEPTIDE TAU |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005555A true MX2020005555A (es) | 2020-08-20 |
Family
ID=66247701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005555A MX2020005555A (es) | 2017-10-27 | 2018-10-26 | Construcciones inmunogenicas de peptidos de tau. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11773148B2 (es) |
EP (1) | EP3700558A4 (es) |
JP (2) | JP2021508673A (es) |
KR (1) | KR20200083524A (es) |
CN (1) | CN111405908A (es) |
AU (1) | AU2018355574A1 (es) |
BR (1) | BR112020008202A2 (es) |
CA (1) | CA3079236A1 (es) |
MX (1) | MX2020005555A (es) |
SG (1) | SG11202003624SA (es) |
TW (1) | TWI804521B (es) |
WO (1) | WO2019084488A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2585252A (en) * | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
US20230093678A1 (en) * | 2020-01-28 | 2023-03-23 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
CN116554342A (zh) * | 2022-01-29 | 2023-08-08 | 元本(珠海横琴)生物科技有限公司 | 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
JP4974609B2 (ja) | 2006-08-22 | 2012-07-11 | 旭化成イーマテリアルズ株式会社 | フィルム状電子機器用部材 |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
SG177637A1 (en) | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
CN102118415A (zh) | 2009-12-31 | 2011-07-06 | 上海博泰悦臻电子设备制造有限公司 | 汽车信息系统 |
US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) * | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US9102752B2 (en) | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
MX2019015286A (es) * | 2017-06-16 | 2020-08-17 | United Neuroscience | Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. |
US20220273779A1 (en) * | 2018-11-19 | 2022-09-01 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
-
2018
- 2018-10-26 MX MX2020005555A patent/MX2020005555A/es unknown
- 2018-10-26 CN CN201880069699.3A patent/CN111405908A/zh active Pending
- 2018-10-26 JP JP2020523430A patent/JP2021508673A/ja active Pending
- 2018-10-26 WO PCT/US2018/057840 patent/WO2019084488A1/en unknown
- 2018-10-26 SG SG11202003624SA patent/SG11202003624SA/en unknown
- 2018-10-26 US US16/759,584 patent/US11773148B2/en active Active
- 2018-10-26 KR KR1020207015232A patent/KR20200083524A/ko unknown
- 2018-10-26 EP EP18871080.0A patent/EP3700558A4/en active Pending
- 2018-10-26 BR BR112020008202-3A patent/BR112020008202A2/pt unknown
- 2018-10-26 AU AU2018355574A patent/AU2018355574A1/en active Pending
- 2018-10-26 CA CA3079236A patent/CA3079236A1/en active Pending
- 2018-10-29 TW TW107138171A patent/TWI804521B/zh active
-
2023
- 2023-11-02 JP JP2023188329A patent/JP2024012498A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020117191A3 (es) | 2022-02-28 |
AU2018355574A1 (en) | 2020-05-14 |
JP2024012498A (ja) | 2024-01-30 |
WO2019084488A1 (en) | 2019-05-02 |
KR20200083524A (ko) | 2020-07-08 |
CN111405908A (zh) | 2020-07-10 |
TW201922775A (zh) | 2019-06-16 |
CA3079236A1 (en) | 2019-05-02 |
RU2020117191A (ru) | 2021-12-01 |
BR112020008202A2 (pt) | 2020-10-27 |
US11773148B2 (en) | 2023-10-03 |
US20210101948A1 (en) | 2021-04-08 |
SG11202003624SA (en) | 2020-05-28 |
EP3700558A1 (en) | 2020-09-02 |
EP3700558A4 (en) | 2022-03-09 |
TWI804521B (zh) | 2023-06-11 |
JP2021508673A (ja) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
WO2018234793A3 (en) | Antibodies | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
PH12019500365A1 (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
MX2020006105A (es) | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
EA202190807A1 (ru) | Антитела к синуклеину | |
MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
NZ762312A (en) | Anti-pacap antibody | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
PH12019502694A1 (en) | Anti-trkb antibodies | |
EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
MX2021015501A (es) | Anticuerpos y metodos de uso. | |
EA202090971A1 (ru) | Способы применения и композиции, содержащие дулаглутид | |
WO2024015611A3 (en) | Tau peptide immunogen constructs | |
EA202192418A1 (ru) | Способы лечения al-амилоидоза | |
EA202092121A1 (ru) | Антитела против cd73 и их применения |